ORIGINAL RESEARCH article
Front. Psychol.
Sec. Psychology for Clinical Settings
Volume 16 - 2025 | doi: 10.3389/fpsyg.2025.1533663
This article is part of the Research TopicOptimizing the Therapeutic Potential in Clinical Settings: Leveraging Placebos and Mitigating Nocebo EffectsView all 10 articles
Talking placebo: A qualitative study of patients' attitudes towards open-label placebo implementation into clinical practice
Provisionally accepted- 1University of Basel, Basel, Switzerland
- 2University Hospital of Basel, Basel, Basel-Stadt, Switzerland
- 3Brown University, Providence, Rhode Island, United States
- 4Rhode Island Hospital, Providence, Rhode Island, United States
- 5Uppsala University, Uppsala, Uppsala, Sweden
- 6Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States
- 7University of Zurich, Zürich, Zürich, Switzerland
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: For more than a decade, studies have supported the efficacy and safety of placebos without deception -so-called open-label placebos (OLPs) -to harness placebo effects in primary care while aligning with key ethical principles. Since treatment acceptance, feasibility, and successful implementation of novel interventions into clinical practice depend on patients' attitudes, patients' perspectives, perceived obstacles, and ideas on OLP use in clinical practice have yet to be elucidated.Therefore, patient and public involvement is increasingly demanded in research and its implementation into clinical practice. Qualitative research offers a unique opportunity to comprehensively understand attitudes, expectations, perceived benefits, and barriers from a patient's point of view. Thus, we studied patients' attitudes, concerns, and ideas towards OLP implementation into clinical practice with focus group discussions (FGDs).In 2022, three exploratory online FGDs, each including two patients with the same condition, were conducted with adult patients affected by chronic back pain (n=2), chronic migraine (n=2), or chemotherapy-induced emesis/nausea (n=2). Physicians recruited participants in three outpatient clinics at the University Hospital Basel in Switzerland. The FGDs were held online for 60 minutes. Qualitative data was analyzed using Reflexive Thematic Analysis, applying an inductivedeductive hybrid approach within a social constructivist framework.In total, five semantic-latent subthemes were identified, entailing: i) Placebos: Promising but risky; ii) Acceptance of OLPs depends on a myriad; iii) Be trustworthy, but deception may be necessary; iv) Harnessing placebo effects without placebos; v) From bench to bedside: Clinical transference of OLPs. The themes reflect an in-depth discussion of the usage of OLPs in the clinical context, accompanied by different ambivalences regarding implementation, prerequisites, and the provider role.
Keywords: open placebo, Patients, attitudes, Focus Groups, qualitative research. 25 hat gelöscht: -label hat gelöscht:, patients and public involvement
Received: 24 Nov 2024; Accepted: 19 Jun 2025.
Copyright: © 2025 Frey Nascimento, Bakis, Gaab, Schneider, Papadopoulou, Ritter, Bernstein, Blease and Locher. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Antje Frey Nascimento, University of Basel, Basel, Switzerland
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.